About: Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication
Creator	Basler, Christopher Chvatal, Stacie Jureka, Alexander Nicolini, Anthony Silvas, Jesus
Source	BioRxiv; Medline; PMC
abstract	Therapeutics targeting replication of SARS coronavirus 2 (SARS-CoV-2) are urgently needed. Coronaviruses rely on host membranes for entry, establishment of replication centers and egress. Compounds targeting cellular membrane biology and lipid biosynthetic pathways have previously shown promise as antivirals and are actively being pursued as treatments for other conditions. Here, we tested small molecule inhibitors that target membrane dynamics or lipid metabolism. Included were inhibitors of the PI3 kinase VPS34, which functions in autophagy, endocytosis and other processes; Orlistat, an inhibitor of lipases and fatty acid synthetase, is approved by the FDA as a treatment for obesity; and Triacsin C which inhibits long chain fatty acyl-CoA synthetases. VPS34 inhibitors, Orlistat and Triacsin C inhibited virus growth in Vero E6 cells and in the human airway epithelial cell line Calu-3, acting at a post-entry step in the virus replication cycle. Of these the VPS34 inhibitors exhibit the most potent activity.
has issue date	2020-07-20(xsd:dateTime)
bibo:doi	10.1101/2020.07.18.210211
bibo:pmid	32743584
has license	cc-by-nc-nd
sha1sum (hex)	cd5fcc7d4d22908916a78534e66fc4f7006ca8ca
schema:url	https://doi.org/10.1101/2020.07.18.210211
resource representing a document's title	Inhibitors of VPS34 and lipid metabolism suppress SARS-CoV-2 replication
has PubMed Central identifier	PMC7386504
has PubMed identifier	32743584
schema:publication	bioRxiv
resource representing a document's body	covid:cd5fcc7d4d22908916a78534e66fc4f7006ca8ca#body_text
is schema:about of	named entity 'replication' named entity 'SARS-CoV-2' named entity 'VPS34' named entity 'fatty acids' named entity 'SARS-CoV-2' named entity 'therapeutic development' named entity 'triacylglycerol' named entity 'bioRxiv' named entity 'MOIs' named entity 'virus replication' named entity 'nucleoprotein' named entity 'DMSO' named entity 'SARS-CoV-2' named entity 'Supernatants' named entity 'cytotoxicity' named entity 'VPS34' named entity 'autophagy' named entity 'SARS-CoV-2' named entity 'Vero E6 cells' named entity 'viruses' named entity 'positive-sense' named entity 'bioRxiv' named entity 'cytoplasmic' named entity 'Vero E6' named entity 'mouse hepatitis virus' named entity '0.01' named entity 'SARS-CoV-2' named entity 'ERAD' named entity 'lipid' named entity 'lipid metabolism' named entity 'SARS-CoV-2' named entity 'VPS34' named entity 'cytotoxicity' named entity 'peer review' named entity 'HCV' named entity 'COVID' named entity 'Calu-3' named entity 'nucleoprotein' named entity 'innate immune response' named entity 'coronaviruses' named entity 'Vero E6' named entity 'infection' named entity 'Viruses' named entity 'Orlistat' named entity 'IC50s' named entity 'Orlistat' named entity 'peer review' named entity 'infection' named entity 'ATG5' named entity 'Triacsin C' named entity 'cytotoxicity' named entity 'fluorescence' named entity 'Vero E6' named entity 'IC50' named entity 'Remdesivir' named entity 'h.p.' named entity 'lipid droplet' named entity 'infection' named entity 'SARS-CoV-2' named entity 'Remdesivir' named entity '0.01' named entity 'Remdesivir' named entity 'human health' named entity 'Vero E6' named entity 'Orlistat' named entity 'nucleoprotein' named entity 'morphology' named entity 'SARS-CoV-2' named entity 'HCV' named entity 'membrane trafficking' named entity 'CoA' named entity 'cytoplasm' named entity 'dsRNA' named entity 'membrane vesicles' named entity 'SARS-CoV-2' named entity 'metabolites' named entity 'toxicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software